Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 36 Issue 5
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2018  >  36(5): 433-437

QIAO Liye, FANG Li, CAO Yanli, LU Yin, SU Hua, WANG Shudong. Determination of aloe-emodin,rhein,emodin,chrysophanol and physcion in Xinbaoshen tablets by HPLC[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 438-440. doi: 10.3969/j.issn.1006-0111.2015.05.015
Citation: XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Overweight might be a risk factor of acute mountain sickness: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
shu

Overweight might be a risk factor of acute mountain sickness: a Meta-analysis

doi: 10.3969/j.issn.1006-0111.2018.05.011

  • Department of Pharmacy, Lanzhou General Hospital, Lanzhou 730050, China

  • Received Date: 2018-03-20
  • Rev Recd Date: 2018-07-03
  • Objective Overweight might be a risk factor of acute mountain sickness (AMS) but its efficacy on developing AMS remained controversial. To study the role of overweight in AMS by a Meta-analysis. Methods A comprehensive literature search (last update, February 28th 2018) was carried out by searching electronic databases for full texts of studies which compared incidence of AMS in overweight with non-overweight individuals. The primary outcome measure for this meta-analysis was the incidence of AMS. Mantel-Haenszel random effect model was used to aggregate data. Heterogeneity of included trials was interpreted by I2 values. A α level of 0.05 was used as the level of significance. The results were reported in a forest plot with 95% CI. Revman 5.0 software provided by the Cochrane Collaboration was used for data processing and analysis. Results AMS occurred in 300 of 566 (53%) in overweight individuals and in 338 of 1 006 (34%) in non-overweight individuals. Compared with non-overweight individuals and independent of the baseline risk ratio (RR), the combined RR of developing AMS in overweight individuals was 2.02 (95% CI 1.08 to 3.76, Z=2.21, P=0.03). It was suggested that obese was a risk factor for developing AMS. The five included studies had high heterogeneity (I2=94%). Conclusion Although further in-depth studies were needed to confirm the function of overweight in the development of AMS, according to a limited number of studies, overweight might be a risk factor of AMS. Therefore, overweight individuals should be provided adequate prophylaxis against AMS before ascent to high altitude.
  • [1] BARTSCH P,SWENSON ER. Clinical practice:acute high-altitude illnesses[J].N Engl J Med, 2013, 368(24):2294-2302.
    [2] SCHNEIDER M, BERNASCH D, WEYMANN J, et al. Acute mountain sickness:influence of susceptibility, preexposure, and ascent rate[J].Med Sci Sports Exerc, 2002, 34(12):1886-1891.
    [3] FIORE DC, HALL S,SHOJA P. Altitude illness:risk factors, prevention, presentation, and treatment[J].Am Fam Physician, 2010, 82(9):1103-1110.
    [4] KAYSER B,VERGES S. Hypoxia, energy balance and obesity:from pathophysiological mechanisms to new treatment strategies[J].Obes Rev, 2013, 14(7):579-592.
    [5] ROACH RC, HOUSTON CS, HONIGMAN B, et al. How well do older persons tolerate moderate altitude[J].West J Med, 1995, 162(1):32-36.
    [6] RI-LI G, CHASE PJ, WITKOWSKI S, et al. Obesity:associations with acute mountain sickness[J].Ann Intern Med, 2003, 139(4):253-257.
    [7] HIRATA K, MASUYAMA S,SAITO A. Obesity as risk factor for acute mountain sickness[J].Lancet,1989,2(8670):1040-1041.
    [8] MCDEVITT M, MCINTOSH SE, RODWAY G, et al. Risk determinants of acute mountain sickness in trekkers in the Nepali Himalaya:a 24-year follow-up[J].Wilderness Environ Med, 2014, 25(2):152-159.
    [9] WU TY, DING SQ, LIU JL, et al. Who should not go high:chronic disease and work at altitude during construction of the Qinghai-Tibet railroad[J].High Alt Med Biol, 2007, 8(2):88-107.
    [10] YANG B, SUN ZJ, CAO F, et al. Obesity is a risk factor for acute mountain sickness:a prospective study in Tibet railway construction workers on Tibetan plateau[J].Eur Rev Med Pharmacol Sci, 2015, 19(1):119-122.
    [11] GAILLARD S, DELLASANTA P, LOUTAN L, et al. Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal:a 12-year follow-up[J].High Alt Med Biol, 2004, 5(4):410-419.
    [12] WAGNER DR, FARGO JD, PARKER D, et al. Variables contributing to acute mountain sickness on the summit of Mt Whitney[J].Wilderness Environ Med, 2006, 17(4):221-228.
    [13] HIGGINS JP,THOMPSON SG. Quantifying heterogeneity in a meta-analysis[J].Stat Med, 2002, 21(11):1539-1558.
    [14] GERTSCH JH, LIPMAN GS, HOLCK PS, et al. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache:the Headache Evaluation at Altitude Trial (HEAT)[J].Wilderness Environ Med, 2010, 21(3):236-243.
    [15] GERTSCH JH, CORBETT B, HOLCK PS, et al. Altitude sickness in climbers and efficacy of NSAIDs trial (ASCENT):randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness[J].Wilderness Environ Med, 2012, 23(4):307-315.
    [16] LIPMAN GS, KANAAN NC, HOLCK PS, et al. Ibuprofen prevents altitude illness:a randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories[J].Ann Emerg Med, 2012, 59(6):484-490.
    [17] HSU TY, WENG YM, CHIU YH, et al. Rate of ascent and acute mountain sickness at high altitude[J].Clin J Sport Med, 2015, 25(2):95-104.
    [18] WANG SH, CHEN YC, KAO WF, et al. Epidemiology of acute mountain sickness on Jade Mountain, Taiwan:an annual prospective observational study[J].High Alt Med Biol, 2010, 11(1):43-49.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0400.250.50.7511.25Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 83.8 %FULLTEXT: 83.8 %META: 14.3 %META: 14.3 %PDF: 1.9 %PDF: 1.9 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 15.1 %其他: 15.1 %其他: 0.8 %其他: 0.8 %Chile: 0.5 %Chile: 0.5 %United States: 0.5 %United States: 0.5 %[]: 0.3 %[]: 0.3 %上海: 3.0 %上海: 3.0 %临汾: 0.5 %临汾: 0.5 %北京: 11.1 %北京: 11.1 %哈尔滨: 0.3 %哈尔滨: 0.3 %宁波: 0.3 %宁波: 0.3 %广州: 0.3 %广州: 0.3 %张家口: 0.8 %张家口: 0.8 %恩施市恩施: 0.3 %恩施市恩施: 0.3 %日喀则: 1.6 %日喀则: 1.6 %曲靖: 0.3 %曲靖: 0.3 %杭州: 0.3 %杭州: 0.3 %武汉: 0.3 %武汉: 0.3 %芒廷维尤: 25.3 %芒廷维尤: 25.3 %衢州: 0.5 %衢州: 0.5 %西宁: 33.7 %西宁: 33.7 %赤峰: 0.3 %赤峰: 0.3 %运城: 1.3 %运城: 1.3 %郑州: 0.3 %郑州: 0.3 %银川: 0.3 %银川: 0.3 %长治: 0.3 %长治: 0.3 %阳泉: 0.3 %阳泉: 0.3 %黄冈: 1.6 %黄冈: 1.6 %其他其他ChileUnited States[]上海临汾北京哈尔滨宁波广州张家口恩施市恩施日喀则曲靖杭州武汉芒廷维尤衢州西宁赤峰运城郑州银川长治阳泉黄冈Highcharts.com

  • Cited by

    Periodical cited type(10)

    1. 李金慈，乔立业，江静怡，姜俊翔，苏华. 基于UPLC色谱指纹图谱及化学模式识别的新保肾片质量控制研究. 中国药师. 2021(06): 1193-1197 .
    2. 周捷，阮健，袁静. 清热明目茶HPLC特征指纹图谱研究及多成分含量测定. 药物分析杂志. 2020(02): 312-320 .
    3. 万娜，林环玉，伍振峰，赵曼茜，滕传震，杨明，郑琴. 基于中药粒子设计结合近红外光谱技术研究清润丸原料粉末的混合均匀性. 中草药. 2020(17): 4425-4432 .
    4. 刘小翠，邓斌，张琪琳. 益肾排毒丸的稳定性研究. 中国医药导报. 2019(13): 29-32 .
    5. 文花，刘燕，董武，白玉霞. HPLC法同时测定蒙药给喜古讷-6中芦荟大黄素、大黄酸、大黄素、大黄酚、大黄素甲醚的含量. 中国民族医药杂志. 2019(08): 41-43 .
    6. 易伟，李思，吴晶晶，苏华，王曙东. 4种大黄制剂微生物限度检查方法验证及分析. 中国药业. 2018(22): 33-37 .
    7. 王俊丽，李加恒，胡中慧，张雅滨，王小晶，丁宏伟，陈璇翾. HPLC法测定润通茶中大黄素和大黄酚的含量. 西北国防医学杂志. 2017(08): 494-496 .
    8. 申伟培，曾铮. HPLC同时测定清火胶囊中芦荟大黄素、大黄素和大黄酚含量的方法. 广西医科大学学报. 2016(05): 899-902 .
    9. 马惠玲，谢鑫，麦曦，刘阳，刘斌，杜巧丽. 高效液相色谱法测定黄连上清丸中芦荟大黄素和大黄酸的含量. 南昌大学学报(医学版). 2016(03): 16-19 .
    10. 丁晓彦，刘青，贾元印，赵渤年. HPLC法测定首乌益智胶囊中大黄素和大黄素甲醚的含量. 山东科学. 2016(05): 36-40 .

    Other cited types(0)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(3132) PDF downloads(293) Cited by(10)

Related
Proportional views

Overweight might be a risk factor of acute mountain sickness: a Meta-analysis

doi: 10.3969/j.issn.1006-0111.2018.05.011
  • Department of Pharmacy, Lanzhou General Hospital, Lanzhou 730050, China
  • Received Date: 2018-03-20
  • Rev Recd Date: 2018-07-03

Abstract: Objective Overweight might be a risk factor of acute mountain sickness (AMS) but its efficacy on developing AMS remained controversial. To study the role of overweight in AMS by a Meta-analysis. Methods A comprehensive literature search (last update, February 28th 2018) was carried out by searching electronic databases for full texts of studies which compared incidence of AMS in overweight with non-overweight individuals. The primary outcome measure for this meta-analysis was the incidence of AMS. Mantel-Haenszel random effect model was used to aggregate data. Heterogeneity of included trials was interpreted by I2 values. A α level of 0.05 was used as the level of significance. The results were reported in a forest plot with 95% CI. Revman 5.0 software provided by the Cochrane Collaboration was used for data processing and analysis. Results AMS occurred in 300 of 566 (53%) in overweight individuals and in 338 of 1 006 (34%) in non-overweight individuals. Compared with non-overweight individuals and independent of the baseline risk ratio (RR), the combined RR of developing AMS in overweight individuals was 2.02 (95% CI 1.08 to 3.76, Z=2.21, P=0.03). It was suggested that obese was a risk factor for developing AMS. The five included studies had high heterogeneity (I2=94%). Conclusion Although further in-depth studies were needed to confirm the function of overweight in the development of AMS, according to a limited number of studies, overweight might be a risk factor of AMS. Therefore, overweight individuals should be provided adequate prophylaxis against AMS before ascent to high altitude.

QIAO Liye, FANG Li, CAO Yanli, LU Yin, SU Hua, WANG Shudong. Determination of aloe-emodin,rhein,emodin,chrysophanol and physcion in Xinbaoshen tablets by HPLC[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 438-440. doi: 10.3969/j.issn.1006-0111.2015.05.015
Citation: XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Overweight might be a risk factor of acute mountain sickness: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
shu

    HTML

Reference (18)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return